{"filings":[{"id":2105721,"accession_number":"0001628280-26-054273","cik":1770787,"company_name":"10x Genomics, Inc.","ticker":"TXG","form_type":"8-K","filed_at":"2026-08-06T20:03:51+00:00","items":["2.02","9.01"],"status":"ready","headline":"10x Genomics Q2 revenue $151M (+3% ex-settlements); raises FY2026 guidance to $610-630M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $151.0M, up 3% YoY excluding patent settlement revenue; gross margin 74% vs 72%.","Operating loss $19.6M vs prior-year operating income $30.1M; net loss $17.9M vs net income $34.5M.","Acquired Proteintech Genomics for protein detection; collaborations with Cleveland Clinic and Lausanne University Hospital.","Raises FY2026 revenue guidance to $610-630M from $600-625M, representing 2-5% growth ex-settlements.","Cash and marketable securities $552.0M as of June 30, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":3482408359.5491962,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":919756,"accession_number":"0001628280-26-041651","cik":1770787,"company_name":"10x Genomics, Inc.","ticker":"TXG","form_type":"8-K","filed_at":"2026-06-08T20:46:52+00:00","items":["5.07"],"status":"ready","headline":"All proposals approved at 10x Genomics 2026 annual meeting: directors elected, auditor ratified, say-on-pay passes","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Serge Saxonov, Benjamin Hindson, and John Stuelpnagel elected as Class I directors with ~91% of votes cast (excluding broker non-votes).","Ratification of Ernst & Young as independent auditor for FY2026 approved with ~99.4% of votes cast.","Non-binding advisory vote on executive compensation approved with ~98.4% of votes cast (excluding broker non-votes).","Approx. 90.5% of eligible votes represented at the meeting; 117.5M shares present."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.15,"market_cap_usd":3482408359.5491962,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95329,"accession_number":"0001628280-26-032073","cik":1770787,"company_name":"10x Genomics, Inc.","ticker":"TXG","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"10x Genomics Q1 2026 net loss narrows to $13.5M; launches Atera platform","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $150.8M (-3% YoY); +9% excluding $16.8M one-time license/royalty in Q1 2025.","Gross margin 70% vs 68%; operating loss $17M vs $39.3M prior year.","Net loss $13.5M vs $34.4M; cash $539.8M (+$112.9M YoY).","Launched Atera spatial whole-transcriptome platform; shipping expected H2 2026.","FY 2026 revenue guidance maintained at $600M-$625M (0-4% growth ex-2025 one-time)."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.1,"consensus_revenue_estimate":null,"consensus_revenue_actual":150843000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":3482408359.5491962,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108293,"accession_number":"0001628280-26-007673","cik":1770787,"company_name":"10x Genomics, Inc.","ticker":"TXG","form_type":"8-K","filed_at":"2026-02-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"10x Genomics Q4 revenue $166M (+1% YoY); FY26 guidance $600-625M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2025 revenue $166.0M (+1% YoY); FY25 $642.8M (+5%), ex-settlements $598.7M (-2%).","Q4 net loss $16.3M vs $49.0M loss YoY; FY25 net loss $43.5M vs $182.6M loss YoY.","Operating expenses down 18% Q4 and 17% FY; gross margin 68% Q4 and 69% FY.","FY2026 revenue guidance $600-625M (0-4% growth ex-2025 settlements).","Cash and equivalents $523.4M at year-end, up $130M vs prior year."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.35,"consensus_revenue_estimate":null,"consensus_revenue_actual":642823000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":3482408359.5491962,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108292,"accession_number":"0001628280-26-001808","cik":1770787,"company_name":"10x Genomics, Inc.","ticker":"TXG","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"10x Genomics reports preliminary Q4 rev $166M (+1% YoY); FY 2025 rev $642.8M incl. $44.1M settlements","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 consumables rev $141.7M (+6% YoY); Spatial consumables up 14% YoY to $41.0M.","Q4 instruments rev $15.5M (-36% YoY); Single Cell instruments down 44% YoY.","Full year rev ex-settlements $598.7M (-2% YoY); instruments rev down 39%.","Cash & securities ~$520M at Dec 31, 2025; cumulative instruments: >6,400 Chromium, >1,500 Spatial.","Single Cell consumables reactions sold increased >20% vs prior year."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.35,"consensus_revenue_estimate":null,"consensus_revenue_actual":642823000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":3482408359.5491962,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124740,"accession_number":"0001628280-25-052154","cik":1770787,"company_name":"10x Genomics, Inc.","ticker":"TXG","form_type":"8-K","filed_at":"2025-11-14T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"10x Genomics CLO Eric Whitaker retiring Jan 1, 2026; Randy Wu named General Counsel","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Eric Whitaker to retire as Chief Legal Officer effective Jan 1, 2026, will remain as Strategic Counsel with reduced compensation.","Dr. Randy Wu, VP of IP and Litigation, appointed General Counsel and Secretary effective Jan 1, 2026.","Wu joined 10x in August 2016; holds Ph.D. in Biophysics from UCSF and J.D. from Stanford Law School.","CEO Serge Saxonov praised Whitaker's eight-year tenure including IPO and legal strategy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":3482408359.5491962,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124739,"accession_number":"0001770787-25-000058","cik":1770787,"company_name":"10x Genomics, Inc.","ticker":"TXG","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"10x Genomics Q3 revenue $149M (-2% YoY); guides Q4 $154-158M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $149.0M in Q3 2025, down 2% YoY; gross margin 67% vs 70% prior year.","Operating loss improved to $32.2M from $41.5M; net loss $27.5M vs $35.8M.","Cash and marketable securities $482.1M, up $35M sequentially.","Q4 2025 revenue guidance $154-158M (midpoint 6% decline YoY, 5% sequential growth).","Launched next-gen Chromium Flex and Xenium Protein spatial multiomic workflow."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.22,"consensus_revenue_estimate":null,"consensus_revenue_actual":476793000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":3482408359.5491962,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141437,"accession_number":"0001770787-25-000048","cik":1770787,"company_name":"10x Genomics, Inc.","ticker":"TXG","form_type":"8-K","filed_at":"2025-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"10x Genomics Q2 revenue down 5% ex-litigation; net income $34.5M; acquires Scale Bio for $30M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $172.9M including $27.3M patent settlement; adjusted revenue $145.6M (-5% YoY).","GAAP net income $34.5M vs net loss $37.9M YoY; operating income $30.1M.","Gross margin 72% vs 68% YoY; ex-license/royalty gross margin 67%.","Q3 2025 revenue guidance $140M-$144M, reflecting ~$4M China pull-forward.","Agreement to acquire Scale Biosciences for $30M upfront cash/stock plus milestone contingent consideration."],"consensus_eps_estimate":null,"consensus_eps_actual":0.0,"consensus_revenue_estimate":null,"consensus_revenue_actual":327791000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":3482408359.5491962,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159252,"accession_number":"0001770787-25-000040","cik":1770787,"company_name":"10x Genomics, Inc.","ticker":"TXG","form_type":"8-K","filed_at":"2025-06-05T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"10x Genomics stockholders re-elect Sri Kosaraju and Shehnaaz Suliman as Class III directors","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Kosaraju received 189,313,724 votes for and 7,243,542 against; Suliman 168,973,468 for and 27,595,026 against.","Ratification of Ernst & Young as independent auditor for FY2025 passed with 215,766,816 votes for.","Non-binding advisory vote on named executive officer compensation approved with 164,321,765 votes for.","108,937,350 shares present or represented by proxy, representing 87.7% of eligible votes, constituting a quorum."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":3482408359.5491962,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159251,"accession_number":"0001770787-25-000035","cik":1770787,"company_name":"10x Genomics, Inc.","ticker":"TXG","form_type":"8-K","filed_at":"2025-05-14T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"10x Genomics settles patent litigation with Bruker; to receive $68M upfront plus royalties","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Settled all patent litigation with Bruker (formerly NanoString) regarding spatial biology platforms; all claims dismissed with prejudice.","10x expects $68M in upfront nonrefundable payments, paid in equal quarterly installments with interest from Q3 2025 to Q2 2026.","Ongoing royalty payments on licensed products and services for the life of the licensed patents.","Litigation began in 2021–2022 targeting NanoString's GeoMx and CosMx spatial platforms; Bruker assumed liabilities in May 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":3482408359.5491962,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159250,"accession_number":"0001770787-25-000031","cik":1770787,"company_name":"10x Genomics, Inc.","ticker":"TXG","form_type":"8-K","filed_at":"2025-05-08T23:59:59+00:00","items":["2.02","2.05","9.01"],"status":"ready","headline":"10x Genomics revenue ex-settlement falls 2% YoY; cuts 8% workforce, withdraws FY guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 revenue $154.9M incl $16.8M patent settlement; ex-settlement $138.1M, down 2% YoY.","Net loss $34.4M vs $59.9M YoY; operating loss $39.3M, improved from $61.5M.","Cutting ~8% of global workforce; expects $5.5-6.5M severance in Q2 2025.","Withdraws full-year 2025 guidance citing US academic/government funding uncertainty.","Q2 2025 revenue guidance $138-142M (ex-settlement), 1% sequential growth at midpoint."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.28,"consensus_revenue_estimate":null,"consensus_revenue_actual":154883000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":3482408359.5491962,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177687,"accession_number":"0001770787-25-000011","cik":1770787,"company_name":"10x Genomics, Inc.","ticker":"TXG","form_type":"8-K","filed_at":"2025-02-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"10x Genomics Q4 revenue down 10% YoY to $165M; FY2024 net loss $182.6M; guidance ~flat","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2024 revenue $165.0M (-10% YoY); full year $610.8M (-1% YoY).","Q4 operating loss $49.8M, net loss $49.0M (unchanged YoY).","Full year 2024 net loss $182.6M, improved from $255.1M loss in 2023.","FY2025 revenue guidance $610M-$630M (0-3% growth); midpoint implies double-digit growth for Chromium and spatial.","Cash and securities $393.4M; launched Billion Cells Project with CZI and Ultima Genomics."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.52,"consensus_revenue_estimate":null,"consensus_revenue_actual":610785000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":3482408359.5491962,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177686,"accession_number":"0001770787-25-000003","cik":1770787,"company_name":"10x Genomics, Inc.","ticker":"TXG","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"10x Genomics reports preliminary Q4 2024 revenue of $165M, down 10% YoY but up 9% sequentially","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY2024 revenue ~$610.8M (-1% YoY); Q4 revenue ~$165M (-10% YoY, +9% sequentially).","Instruments Q4 revenue $24.4M (-37% YoY); consumables $133.5M (-5% YoY); services $7.1M (+35% YoY).","Cumulative instruments deployed >7,000; cash and equivalents ~$393M.","Preliminary and unaudited; subject to adjustment after year-end close."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.52,"consensus_revenue_estimate":null,"consensus_revenue_actual":610785000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":3482408359.5491962,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194406,"accession_number":"0001770787-24-000071","cik":1770787,"company_name":"10x Genomics, Inc.","ticker":"TXG","form_type":"8-K","filed_at":"2024-10-29T23:59:59+00:00","items":["2.02","5.02","9.01"],"status":"ready","headline":"10x Genomics Q3 revenue $151.7M (-1% YoY); cuts FY2024 revenue guidance to $595-605M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $151.7M, down 1% YoY; net loss improved to $35.8M from $93.0M.","FY2024 revenue guidance lowered to $595-605M from prior $640-660M (3% decline YoY midpoint).","CEO cites greater-than-anticipated disruption from sales restructuring and cautious spending.","Board member Mathai Mammen resigned effective Oct 24, 2024 due to professional time commitments.","Launched GEM-X Flex, GEM-X Universal Multiplex, and Chromium Xo instruments."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.11,"consensus_revenue_estimate":null,"consensus_revenue_actual":445764000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":3482408359.5491962,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194405,"accession_number":"0001770787-24-000064","cik":1770787,"company_name":"10x Genomics, Inc.","ticker":"TXG","form_type":"8-K","filed_at":"2024-10-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"10x Genomics preliminary Q3 revenue $151.7M, down 1% YoY; instruments revenue falls 46%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue of ~$151.7M, down 1% YoY; instruments revenue $19.1M (-46%), consumables $126.2M (+10%), services $6.4M (+48%).","Americas revenue $87.8M (-11% YoY); EMEA $37.9M (+18%); APAC $26.0M (+15%).","CEO cites commercial reorganization disruption and cautious customer spending on capital equipment as key headwinds.","Cash and equivalents ~$398M as of Sept 30; full-year 2024 guidance to be discussed on October 29 earnings call."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.11,"consensus_revenue_estimate":null,"consensus_revenue_actual":445764000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":3482408359.5491962,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210732,"accession_number":"0001770787-24-000058","cik":1770787,"company_name":"10x Genomics, Inc.","ticker":"TXG","form_type":"8-K","filed_at":"2024-08-08T23:59:59+00:00","items":["2.02","5.02","8.01","9.01"],"status":"ready","headline":"10x Genomics reports Q2 revenue $153.1M (+4% YoY), guides FY24 down to $640-660M; CFO resigns, Taich appointed","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 revenue $153.1M, +4% YoY; net loss $37.9M vs $62.4M loss in prior year.","Operating expenses down 10% to $146.0M; gross margin flat at 68%.","Full year 2024 revenue guidance lowered to $640-660M from $670-690M (3-7% growth).","CFO Justin McAnear resigns effective Aug 30; Adam Taich appointed CFO effective Aug 12.","Mennah Moustafa named Chief Commercial Officer effective Aug 1."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.82,"consensus_revenue_estimate":null,"consensus_revenue_actual":294110000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":3482408359.5491962,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210731,"accession_number":"0001770787-24-000048","cik":1770787,"company_name":"10x Genomics, Inc.","ticker":"TXG","form_type":"8-K","filed_at":"2024-07-11T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"10x Genomics appoints Sarah A. Teichmann to Board of Directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Effective July 10, 2024; Class II director with term expiring at 2027 annual meeting.","Teichmann is Chair in Stem Cell Medicine at University of Cambridge and co-chair of Human Cell Atlas.","She receives $55,000 annual cash retainer plus initial RSU grant valued at $400,000.","Annual RSU grant of $215,000 on annual meeting date; both grants vest over time with continued service.","Also serves as VP at GSK and CSO at EnsoCell Therapeutics; brings genomics and leadership expertise."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":3482408359.5491962,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229115,"accession_number":"0001770787-24-000044","cik":1770787,"company_name":"10x Genomics, Inc.","ticker":"TXG","form_type":"8-K","filed_at":"2024-06-20T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"10x Genomics appoints Alan V. Mateo to Board of Directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Alan V. Mateo appointed as Class II director effective June 18, 2024, term until 2027 annual meeting.","Mateo previously Executive VP Global Sales at Veeva Systems, executive roles at Medidata Solutions and PeopleSoft.","Receives $55k annual cash retainer, $400k initial RSU grant (July 31, 2024), and $215k annual RSU grant.","Compensation includes standard indemnification agreement; eligible for additional committee service retainers."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":3482408359.5491962,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229114,"accession_number":"0001770787-24-000040","cik":1770787,"company_name":"10x Genomics, Inc.","ticker":"TXG","form_type":"8-K","filed_at":"2024-06-13T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"10x Genomics annual meeting results: director elected, auditor ratified, bylaw amendment fails","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Director Kimberly J. Popovits elected with 198.6M votes for, 18.7M against.","Ernst & Young ratified as auditor with 228.8M votes for.","Bylaw amendment to let board amend without stockholder approval defeated (112.7M for, 104.5M against).","Non-binding executive compensation approved with 180.8M votes for."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.15,"market_cap_usd":3482408359.5491962,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229113,"accession_number":"0001770787-24-000035","cik":1770787,"company_name":"10x Genomics, Inc.","ticker":"TXG","form_type":"8-K","filed_at":"2024-04-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"10x Genomics Q1: revenue up 5% to $141M, net loss widens to $59.9M; guidance reaffirmed","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue of $141.0M (+5% YoY); gross margin 66% vs 73% due to product mix shift to Xenium instruments.","Net loss widened to $59.9M from $50.7M; operating loss $61.5M vs $52.0M.","FY2024 revenue guidance maintained at $670M-$690M, representing 8-12% growth over FY2023.","Shipped Visium HD for spatial discovery, GEM-X single cell technology, and Xenium cell segmentation products.","Operating expenses up 3% to $154.4M; stock-based compensation declined to $36.1M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.5,"consensus_revenue_estimate":null,"consensus_revenue_actual":141006000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":3482408359.5491962,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":247719,"accession_number":"0001770787-24-000015","cik":1770787,"company_name":"10x Genomics, Inc.","ticker":"TXG","form_type":"8-K","filed_at":"2024-02-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"10x Genomics Q4 revenue up 18% to $184M but net loss widens to $49M; FY2024 guidance 8-12% growth","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2023 revenue $184.0M (+18% YoY); FY2023 revenue $618.7M (+20% YoY).","Q4 gross margin 63% vs 76% YoY due to higher mix of Spatial instruments.","Q4 operating loss $55.2M (vs $23.1M), including $38.9M stock-based comp and $19.6M in-process R&D expense.","Full year 2023 net loss $255.1M, widened from $166.0M in 2022.","FY2024 revenue guidance $670M-$690M (8-12% growth); cumulative instruments sold reached 5,966."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.18,"consensus_revenue_estimate":null,"consensus_revenue_actual":618727000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":3482408359.5491962,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":247718,"accession_number":"0001770787-24-000007","cik":1770787,"company_name":"10x Genomics, Inc.","ticker":"TXG","form_type":"8-K","filed_at":"2024-01-16T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"CCO James Wilbur to depart 10x Genomics on Feb 1, 2024; gets severance","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["James Wilbur, Chief Commercial Officer, leaving effective Feb 1, 2024; no disagreement with management.","Severance: six months base salary plus one-time COBRA payment of $14,335.","No 2023 annual performance bonus for Wilbur.","Departure not related to company's operations, financial statements, or policies."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":3482408359.5491962,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":247717,"accession_number":"0001770787-24-000004","cik":1770787,"company_name":"10x Genomics, Inc.","ticker":"TXG","form_type":"8-K","filed_at":"2024-01-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"10x Genomics reports preliminary Q4 revenue of $184M, up 18% YoY; instruments up 72%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Preliminary Q4 2023 revenue ~$184.0M, 18% growth over prior year; full-year revenue ~$618.7M, up 20%.","Q4 instruments revenue ~$38.4M (+72% YoY), driven by Spatial ($27.2M) and Chromium ($11.1M).","Q4 consumables revenue ~$140.3M (+7% YoY); services revenue ~$5.3M (+129% YoY).","Cumulative instruments sold exceeded 5,900 as of year-end 2023, including over 5,150 Chromium, 500 Visium, 250 Xenium.","Final audited results expected in February 2024 earnings call; preliminary figures subject to adjustment."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.18,"consensus_revenue_estimate":null,"consensus_revenue_actual":618727000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":3482408359.5491962,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":265161,"accession_number":"0001770787-23-000051","cik":1770787,"company_name":"10x Genomics, Inc.","ticker":"TXG","form_type":"8-K","filed_at":"2023-11-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"10x Genomics Q3 revenue $153.6M (+17% YoY), net loss $93.0M; raises FY2023 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 2023 revenue $153.6M, up 17% YoY; raised FY2023 guidance to $610-625M.","Gross margin fell to 62% from 77% YoY due to product mix from Xenium instrument placements.","Operating loss $94.8M ($40.0M prior year); includes $41.4M in-process R&D and $40.2M stock comp.","Net loss $93.0M vs $41.9M; cash & securities $356.9M as of Sep 30.","Xenium platform driving demand; launched new panel configurations and Beckman Coulter partnership."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.77,"consensus_revenue_estimate":null,"consensus_revenue_actual":434748000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":3482408359.5491962,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":282360,"accession_number":"0001770787-23-000045","cik":1770787,"company_name":"10x Genomics, Inc.","ticker":"TXG","form_type":"8-K","filed_at":"2023-08-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"10x Genomics Q2 revenue $146.8M (+28% YoY); raises FY2023 guidance to $600-620M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $146.8M in Q2, +28% YoY from $114.6M.","Gross margin 68% vs 76% prior year, down on product mix from new launches.","Net loss $62.4M vs $64.5M YoY; stock-based compensation expense $45.7M.","Raises FY2023 revenue guidance to $600-620M from prior $590-610M, 16-20% growth.","Accelerated Xenium in situ platform momentum; launched Visium CytAssist Gene & Protein Expression assay."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.97,"consensus_revenue_estimate":null,"consensus_revenue_actual":281104000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":3482408359.5491962,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":282359,"accession_number":"0001770787-23-000038","cik":1770787,"company_name":"10x Genomics, Inc.","ticker":"TXG","form_type":"8-K","filed_at":"2023-07-20T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director Bryan Roberts resigns from 10x Genomics board; Popovits joins Audit Committee","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Bryan E. Roberts resigned from the Board and its Audit and Compensation committees effective July 18, 2023.","Resignation due solely to professional time commitments; no disagreement with management or operations.","Kimberly J. Popovits appointed to the Audit Committee effective July 19, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":3482408359.5491962,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":301552,"accession_number":"0001770787-23-000034","cik":1770787,"company_name":"10x Genomics, Inc.","ticker":"TXG","form_type":"8-K","filed_at":"2023-06-16T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Stockholders approve director elections, auditor, and say-on-pay at 2023 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Three Class I directors elected: Hindson, Saxonov, Stuelpnagel, each with >88% votes for.","Ratification of Ernst & Young as independent auditor for FY2023 approved (99.9% votes for).","Non-binding advisory vote on executive compensation passed with ~82% support (188M for, 39M against).","Quorum achieved with 85.5% of eligible votes represented (238.3M of 278.8M votes).","All proposals passed; no broker non-votes on auditor ratification."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":3482408359.5491962,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":301551,"accession_number":"0001770787-23-000031","cik":1770787,"company_name":"10x Genomics, Inc.","ticker":"TXG","form_type":"8-K","filed_at":"2023-05-17T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"10x Genomics wins permanent German injunction against NanoString's CosMx products","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Munich Regional Court issued permanent injunction requiring NanoString to stop selling CosMx SMI instruments and RNA detection reagents in Germany.","Injunction based on infringement of European Patent 2794928B1; German Federal Patent Court preliminarily found patent valid.","10x is seeking additional injunctions against NanoString's CosMx and GeoMx products in US and other jurisdictions.","10x launches special promotions for CosMx customers to transition to its Xenium in situ platform."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":3482408359.5491962,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":301550,"accession_number":"0001770787-23-000026","cik":1770787,"company_name":"10x Genomics, Inc.","ticker":"TXG","form_type":"8-K","filed_at":"2023-05-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"10x Genomics Q1 revenue $134.3M (+17% YoY); net loss $50.7M; raises FY2023 guidance to $590-$610M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $134.3M (+17% YoY); spatial portfolio drove growth, Xenium in first full launch quarter.","Net loss $50.7M vs $42.4M in prior year; operating loss $52.0M incl $42.1M stock-based comp.","Gross margin 73% (down from 78%) due to product mix and inventory write-downs.","Raised FY2023 revenue guidance to $590-610M (prev $580-600M); 14-18% growth.","Cash and marketable securities $418.3M as of March 31."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.44,"consensus_revenue_estimate":null,"consensus_revenue_actual":134285000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":3482408359.5491962,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":321337,"accession_number":"0001770787-23-000006","cik":1770787,"company_name":"10x Genomics, Inc.","ticker":"TXG","form_type":"8-K","filed_at":"2023-02-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"10x Genomics Q4 revenue up 9% to $156.2M; FY net loss triples to $166M, guides FY23 rev $580-600M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2022 revenue $156.2M (+9% YoY); FY 2022 revenue $516.4M (+5% YoY).","Gross margin fell to 76% in Q4 (from 81%) and 77% for FY (from 85%) due to product mix.","Operating loss widened to $23.1M in Q4 and $167.9M for FY, driven by higher stock-based compensation.","Net loss for FY 2022 was $166.0M vs $58.2M in 2021; cash + securities $430M.","FY 2023 revenue guidance $580M-$600M (12-16% growth); began shipping Xenium in situ platform."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.46,"consensus_revenue_estimate":null,"consensus_revenue_actual":516409000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":3482408359.5491962,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":339443,"accession_number":"0001770787-22-000053","cik":1770787,"company_name":"10x Genomics, Inc.","ticker":"TXG","form_type":"8-K","filed_at":"2022-11-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"10x Genomics Q3 revenue up 5% to $131.1M but net loss widens to $41.9M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $131.1M (+5% YoY, +14% QoQ); gross margin 77% (down from 80% in Q3 2021).","Operating loss $40.0M vs $15.9M YoY; net loss $41.9M vs $17.2M YoY, including $33.5M stock-based compensation.","FY2022 revenue guidance reaffirmed at $500-520M; cash & equivalents $452.4M at Sep 30, 2022.","Highlights Xenium in situ platform launch expected later this year and long-read sequencing compatibility."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.31,"consensus_revenue_estimate":null,"consensus_revenue_actual":360177000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":3482408359.5491962,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":356814,"accession_number":"0001770787-22-000047","cik":1770787,"company_name":"10x Genomics, Inc.","ticker":"TXG","form_type":"8-K","filed_at":"2022-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"10x Genomics Q2 revenue $114.6M (-1% YoY); net loss $64.5M vs $11.1M loss","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $114.6M, down 1% YoY; gross margin 76% vs 96% due to $14.7M prior-year royalty reversal.","Operating loss $63.1M (vs $10.3M); net loss $64.5M (vs $11.1M); stock-based comp $36.3M.","FY2022 revenue guidance cut to $500-520M (2-6% growth) from prior expectations.","Headwinds: China lockdowns, European cold-chain logistics delays, execution issues, unfavorable FX.","Launched Fixed RNA Profiling Kit for FFPE; shipped Visium CytAssist; hired Jim Wilbur as CCO."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.94,"consensus_revenue_estimate":null,"consensus_revenue_actual":229105000.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":3482408359.5491962,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":356813,"accession_number":"0001770787-22-000040","cik":1770787,"company_name":"10x Genomics, Inc.","ticker":"TXG","form_type":"8-K","filed_at":"2022-08-03T23:59:59+00:00","items":["2.05"],"status":"ready","headline":"10x Genomics to cut ~8% of workforce; expects $5-6M in severance costs","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reduction in force affecting approximately 8% of global workforce.","Estimated costs of $5M to $6M, primarily cash severance, to be recognized in Q3 2022.","Company cites need to decrease costs and maintain streamlined organization.","Actual costs may differ and additional costs not currently contemplated may arise."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":3482408359.5491962,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":356812,"accession_number":"0001770787-22-000036","cik":1770787,"company_name":"10x Genomics, Inc.","ticker":"TXG","form_type":"8-K","filed_at":"2022-07-14T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"10x Genomics preannounces Q2 rev ~$114.5M (-1% YoY), hires Jim Wilbur as CCO","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Preliminary Q2 rev of ~$114.5M, down ~1% YoY from $115.8M and flat sequentially.","Americas rev grew 8% YoY to $70.9M; EMEA fell 11% to $25.6M; APAC fell 15% to $18.1M.","CEO says results 'fell short of our expectations'; full Q2 results and FY2022 guidance on Aug 8.","Appointed Jim Wilbur, Ph.D., as Chief Commercial Officer effective July 27; outgoing CCO Brad Crutchfield to transition through Dec 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.94,"consensus_revenue_estimate":null,"consensus_revenue_actual":229105000.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":3482408359.5491962,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":375288,"accession_number":"0001770787-22-000032","cik":1770787,"company_name":"10x Genomics, Inc.","ticker":"TXG","form_type":"8-K","filed_at":"2022-06-17T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"10x Genomics stockholders elect three Class III directors at annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Sri Kosaraju, Mathai Mammen, and Shehnaaz Suliman elected as Class III directors for three-year terms.","Ernst & Young LLP ratified as independent auditor for FY2022 with 236,807,826 votes for.","Non-binding advisory vote on executive compensation approved with 218,457,617 votes for."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":3482408359.5491962,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":375287,"accession_number":"0001770787-22-000026","cik":1770787,"company_name":"10x Genomics, Inc.","ticker":"TXG","form_type":"8-K","filed_at":"2022-05-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"10x Genomics Q1 revenue $114.5M (+8% YoY); net loss widens to $42.4M; FY22 guidance maintained","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $114.5M, up 8% YoY from $105.8M; gross margin fell to 78% from 84%.","Net loss $42.4M vs $11.6M in Q1 2021; operating loss $41.7M including $26.0M stock-based comp.","Operating expenses rose 32% to $130.8M driven by higher personnel, R&D, and infrastructure costs.","Cash and marketable securities $539.3M as of March 31, 2022.","Full-year 2022 revenue guidance maintained at $600M-$630M, implying 22-28% growth."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.38,"consensus_revenue_estimate":null,"consensus_revenue_actual":114496000.0,"consensus_period":"2022-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":3482408359.5491962,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":393655,"accession_number":"0001770787-22-000004","cik":1770787,"company_name":"10x Genomics, Inc.","ticker":"TXG","form_type":"8-K","filed_at":"2022-02-16T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"10x Genomics reports FY 2021 revenue $490.5M (+64% YoY); guides FY 2022 revenue $600-630M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $490.5M FY 2021, up 64% from $298.8M in FY 2020; Q4 revenue $143.5M, up 28% from $112.2M.","Gross margin 85% FY 2021 vs 80% in 2020, due to lower royalties and manufacturing efficiencies.","Operating loss $52.3M FY 2021 vs $534.1M in 2020, which included $447.5M acquisition-related R&D charges.","Net loss $58.2M FY 2021 vs $542.7M in 2020; cash and equivalents $587.4M as of Dec 31, 2021.","FY 2022 revenue guidance $600-630M, representing 22-28% growth over FY 2021."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.53,"consensus_revenue_estimate":null,"consensus_revenue_actual":490490000.0,"consensus_period":"2021-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":3482408359.5491962,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":412196,"accession_number":"0001770787-21-000048","cik":1770787,"company_name":"10x Genomics, Inc.","ticker":"TXG","form_type":"8-K","filed_at":"2021-11-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"10x Genomics Q3 revenue $125.3M (+74% YoY); FY2021 guidance raised to $490-500M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $125.3M, up 74% YoY and 8% QoQ; operating loss $15.9M vs $65.3M loss last year.","Gross margin flat at 80%; net loss $17.2M vs $65.8M loss Q3 2020.","Cash $600.4M; began shipping Chromium X instrument.","FY2021 revenue guidance revised to $490-500M (64-67% growth over FY2020)."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.36,"consensus_revenue_estimate":null,"consensus_revenue_actual":346960000.0,"consensus_period":"2021-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":3482408359.5491962,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":430903,"accession_number":"0001770787-21-000041","cik":1770787,"company_name":"10x Genomics, Inc.","ticker":"TXG","form_type":"8-K","filed_at":"2021-08-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"10x Genomics Q2 revenue $115.8M (+170% YoY); settles Bio-Rad litigation","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $115.8M, up 170% YoY and 9% QoQ; net loss narrowed to $11.1M from $40.2M.","Gross margin 96% aided by $14.7M one-time royalty reversal from Bio-Rad settlement.","Launched Chromium X platform and began shipping Visium Spatial Gene Expression for FFPE.","Global settlement with Bio-Rad resolves all outstanding litigation; cross-license agreement.","Maintains FY2021 revenue guidance $480M-$500M, representing 61%-67% growth."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.21,"consensus_revenue_estimate":null,"consensus_revenue_actual":221663000.0,"consensus_period":"2021-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":3482408359.5491962,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":430902,"accession_number":"0001770787-21-000039","cik":1770787,"company_name":"10x Genomics, Inc.","ticker":"TXG","form_type":"8-K","filed_at":"2021-07-27T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"10x Genomics settles all patent litigation with Bio-Rad, enters global cross-license for single cell analysis","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Cross license covers single cell analysis; excludes spatial, in situ, and digital PCR (for 10x).","10x to pay Bio-Rad $29.4M in royalties/interest for past GEM sales; $15.4M reversal in Q2 2021.","Future royalty payments expected to impact gross margins by less than 1% through 2030.","All outstanding litigation dismissed with prejudice.","Agreement term is life of licensed patents."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":3482408359.5491962,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}